Kasagi K, Hatabu H, Tokuda Y, Arai K, Iida Y, Konishi J
Department of Nuclear Medicine, Kyoto University School of Medicine, Japan.
Acta Endocrinol (Copenh). 1988 Mar;117(3):365-72. doi: 10.1530/acta.0.1170365.
By using an assay measuring cAMP production in FRTL-5 thyroid cells, thyroid stimulating antibodies (TSab) were detected in all of 15 patients with euthyroid Graves' disease (EG) and of 26 patients with hyperthyroid Graves' disease (HG). There was no significant difference between TSab activities in EG and in HG. In an effort to elucidate why EG patients remain euthyroid in spite of having TSab, we investigated the effect of the patient's crude immunoglobulin fractions on 125I uptake in FRTL-5 thyroid cells, one of the indices of stimulation subsequent to cAMP production. The 125I uptake stimulating (IUS) activity was positive in 46.7% (7/15) of EG patients and 88.5% (23/26) of HG patients, being significantly lower in the former than in the latter (P less than 0.02). Although the IUS activities significantly correlated with TSab activities in 41 patients with EG and HG (r = 0.784, P less than 0.001), the ratio of IUS to TSab in EG tended to be lower than that in HG. TSH-binding inhibitor immunoglobulins (TBII) activities in EG patients were negative or weakly positive, being significantly lower than those in HG patients (P less than 0.001). Thus, the ratios of TBII to both TSab and IUS activities were significantly higher in HG than in EG (P less than 0.01, P less than 0.001, respectively). The in vitro IUS activities also correlated with TBII activities (r = 0.441, P less than 0.001) and in vivo 99mTc thyroid uptake (r = 0.401, P less than 0.001) in both EG and HG patients.(ABSTRACT TRUNCATED AT 250 WORDS)
通过使用一种测量FRTL-5甲状腺细胞中环磷酸腺苷(cAMP)生成的检测方法,在15例甲状腺功能正常的格雷夫斯病(EG)患者和26例甲状腺功能亢进的格雷夫斯病(HG)患者中均检测到甲状腺刺激抗体(TSab)。EG患者和HG患者的TSab活性无显著差异。为了阐明为什么EG患者尽管有TSab却仍保持甲状腺功能正常,我们研究了患者的粗免疫球蛋白组分对FRTL-5甲状腺细胞中125I摄取的影响,125I摄取是cAMP生成后刺激的指标之一。125I摄取刺激(IUS)活性在46.7%(7/15)的EG患者和88.5%(23/26)的HG患者中呈阳性,前者显著低于后者(P<0.02)。虽然在41例EG和HG患者中IUS活性与TSab活性显著相关(r = 0.784,P<0.001),但EG患者中IUS与TSab的比值往往低于HG患者。EG患者的促甲状腺激素结合抑制性免疫球蛋白(TBII)活性为阴性或弱阳性,显著低于HG患者(P<0.001)。因此,HG患者中TBII与TSab和IUS活性的比值均显著高于EG患者(分别为P<0.01和P<0.001)。在EG和HG患者中,体外IUS活性也与TBII活性相关(r = 0.441,P<0.001)以及与体内99mTc甲状腺摄取相关(r = 0.401,P<0.001)。(摘要截短于250字)